When a drug company gets a patent, it gets a legal monopoly on selling that medicine—usually for 20 years. But evergreening, a strategy where pharmaceutical companies make minor changes to existing drugs to extend patent protection. Also known as patent evergreening, it’s how some brands keep high prices alive long after the original patent should have expired. This isn’t about innovation. It’s about timing. A company might tweak the dosage, switch the pill shape, or add a new coating—none of which make the drug work better—but enough to file a new patent and block generics.
This practice directly impacts generic drugs, lower-cost versions of brand-name medications that become available after patents expire. When evergreening works, generics stay off the market. That means you pay more for the same active ingredient. You see this in drug pricing, the cost of prescription medications, often inflated by patent strategies. For example, a drug like Viagra might get a new extended-release version, or a nasal spray might change its delivery mechanism—just enough to reset the clock. Meanwhile, patients wait years longer for affordable options. The FDA doesn’t stop this. Courts often allow it. And insurance plans? They’re stuck paying the higher price until generics finally break through.
It’s not just about money. Evergreening slows down access to life-saving treatments. When a hepatitis C drug like sofosbuvir gets evergreened, cheaper versions take longer to arrive—delaying cures for thousands. Same with blood pressure meds like nifedipine or nasal sprays like budesonide. The science behind the drug hasn’t changed. But the price tag? It’s still climbing. And while some patents are legitimate improvements, most evergreening moves are legal loopholes, not medical advances.
What’s in the collection below? You’ll find real examples of how this plays out. Posts on authorized generics explain why your pill looks different but works the same. Others show how prior authorization for cheap meds delays treatment. You’ll see how drug interactions, like those between proton pump inhibitors and antifungals, get complicated when patents are stretched. And you’ll learn how to spot when a drug’s price isn’t about cost—it’s about control.
Evergreening lets drug companies extend patents on minor changes to block generics and keep prices high. Learn how this legal tactic works, why it hurts patients, and what’s being done to stop it.
Read More
